Evidence mapPaperPMID 38805166Full record

ReviewCurrent nutrition reports2024

Effects of Phytochemicals on Type 2 Diabetes via MicroRNAs.

Dilek Sivri, Makbule Gezmen-Karadağ

Abstract readReview
In one paragraph

Review in Current nutrition reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Dilek SivriDepartment of Nutrition and Dietetic, Faculty of Health Science, Anadolu University, Eskişehir, Turkey. dileksivri@anadolu.edu.tr.ORCID http://orcid.org/0000-0002-1733-1944
Makbule Gezmen-KaradağDepartment of Nutrition and Dietetic, Faculty of Health Science, Gazi University, Ankara, Turkey.ORCID http://orcid.org/0000-0003-3202-3250

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewType 2 diabetes, characterized by inadequate insulin secretion and resistance, is increasingly prevalent. To effectively manage type 2 diabetes, identifying new therapeutic targets is crucial. MicroRNAs, short noncoding RNA molecules, play a pivotal role in regulating β-cell function, insulin production, and resistance, and show promise as biomarkers for predicting type 2 diabetes onset. Phytochemicals, known for their antioxidant activities, may influence microRNA expression, potentially improving insulin sensitivity and mitigating associated complications. This review aims to explore the significance of microRNA in type 2 diabetes, their potential as biomarkers, and how certain phytochemicals may modulate microRNA expressions to reduce or prevent diabetes and its complications. RECENT

findingsCurrent research suggests that microRNAs show promise as novel therapeutic biomarkers for diagnosing type 2 diabetes and monitoring diabetic complications. Additionally, phytochemicals may regulate microRNAs to control type 2 diabetes, presenting a potential therapeutic strategy. The multifactorial effects of phytochemicals on type 2 diabetes and its complications through microRNAs warrant further research to elucidate their mechanisms. Comprehensive clinical trials are needed to assess the safety and efficacy of phytochemicals and their combinations. Given their ability to modulate microRNAs expression, incorporating phytochemical-rich foods into the diet may be beneficial.

Indexed as

Diabetes Mellitus, Type 2MicroRNAsPhytochemicalsAntioxidantsBiomarkersHumansInsulin ResistanceAntioxidantsBiomarkersMicroRNAsPhytochemicalsInsulin resistanceMicroRNAPhytochemicalsType 2 Diabetes

Identifiers

PMID38805166
PMCPMC11327184

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.